Related references
Note: Only part of the references are listed.Minimal Residual Disease, Metastasis and Immunity
Jordi Badia-Ramentol et al.
BIOMOLECULES (2021)
Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21
Chandra Bose Prabaharan et al.
INVESTIGATIONAL NEW DRUGS (2020)
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures
Anmar M. Nassir
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2020)
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Win Topatana et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Rapid identification of novel independent serum biomarkers in diffuse large B-cell lymphoma
Yi-Qun Che et al.
TRANSLATIONAL CANCER RESEARCH (2020)
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
Lavanya Lokhande et al.
BMC CANCER (2020)
Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
Mats Jerkeman et al.
BLOOD (2020)
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Preetesh Jain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Mats Jerkeman et al.
LANCET HAEMATOLOGY (2018)
Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management
Nigel P. Murray
BIOLOGICAL RESEARCH (2018)
Patient monitoring through liquid biopsies using circulating tumor DNA
Peter Ulz et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis
Florentin Spaeth et al.
CANCER RESEARCH (2017)
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells
A. Tachtsidis et al.
CLINICAL & EXPERIMENTAL METASTASIS (2016)
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells
Xianhui Wang et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study
F. Pauly et al.
BLOOD CANCER JOURNAL (2016)
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study
Lena Nordstrom et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
PARP1-Driven Apoptosis in Chronic Lymphocytic Leukemia
Panagiotis T. Diamantopoulos et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Biomarker Testing for Ovarian Cancer: Clinical Utility of Multiplex Assays
Brian M. Nolen et al.
MOLECULAR DIAGNOSIS & THERAPY (2013)
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
Chris T. Williamson et al.
EMBO MOLECULAR MEDICINE (2012)
Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks
Radha M. Golla et al.
HEMATOLOGICAL ONCOLOGY (2012)
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Matthew J. Schiewer et al.
CANCER DISCOVERY (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates
Roman Gulati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases
Anders Carlsson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Rajesh R. Nair et al.
BIOCHEMICAL PHARMACOLOGY (2010)
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
Victoria J. Weston et al.
BLOOD (2010)
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration
Ganta Vijay Chaitanya et al.
CELL COMMUNICATION AND SIGNALING (2010)
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Chris T. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
E. A. M. Heijnsdijk et al.
BRITISH JOURNAL OF CANCER (2009)
APLF (C2orf13) is a novel component of poly(ADP-ribose) signaling in mammalian cells
Stuart L. Rulten et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer
Katenna Pardali et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2007)
Caspase-mediated cleavage of the stacking protein GRASP65 is required for Golgi fragmentation during apoptosis
JD Lane et al.
JOURNAL OF CELL BIOLOGY (2002)
Share Paper
